

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/085,322	02/28/2002	Abbot F. Clark	1910	8526	
7590 01/04/2006			EXAMINER		
Alcon, Inc.			ZEMAN, ROBERT A		
c/o Alcon Rese Patrick M. Rva	arch, Ltd. n(Q-148), R&D Councel	ART UNIT	PAPER NUMBER		
6201 So. Freew		1645			
Fort Worth, TX 76134-2099			DATE MAILED: 01/04/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Α	Application No. Applicant(s)						
Office Action Summary		1	10/085,322	CLARK, ABBOT	CLARK, ABBOT F.				
		E	xaminer	Art Unit					
		R	obert A. Zeman	1645					
Period fo	The MAILING DATE of this communi or Reply	ication appeal	rs on the cover sheet w	ith the correspondence a	ddress				
WHI(- Exte after - If NO - Faill Any	ORTENED STATUTORY PERIOD FOR CHEVER IS LONGER, FROM THE M. Insions of time may be available under the provisions of SIX (6) MONTHS from the mailing date of this common period for reply is specified above, the maximum state to reply within the set or extended period for reply reply received by the Office later than three months at ed patent term adjustment. See 37 CFR 1.704(b).	AILING DATE of 37 CFR 1.136(a unication. ututory period will a will, by statute, cau	E OF THIS COMMUN). In no event, however, may a pply and will expire SIX (6) MO use the application to become A	ICATION. reply be timely filed NTHS from the mailing date of this of the standoned (35 U.S.C. § 133).					
Status									
1)[🛛	Responsive to communication(s) file	d on 28 Febr	uary 2002.						
2a)□	This action is FINAL . 2b) ☐ This action is non-final.								
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is								
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.								
Disposit	ion of Claims								
4)⊠	4) Claim(s) 1-10 is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
5)□	Claim(s) is/are allowed.								
6)□	Claim(s) is/are rejected.								
7)	Claim(s) is/are objected to.								
8)⊠	8) Claim(s) <u>1-10</u> are subject to restriction and/or election requirement.								
Applicat	ion Papers								
9)[The specification is objected to by the	e Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).									
_	Replacement drawing sheet(s) including		•	- · · · -					
11)	The oath or declaration is objected to	by the Exam	niner. Note the attache	ed Office Action or form P	TO-152.				
Priority (ınder 35 U.S.C. § 119								
•	Acknowledgment is made of a claim t ☐ All b)☐ Some * c)☐ None of:		•	§ 119(a)-(d) or (f).					
	 Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No 								
	3. Copies of the certified copies of				l Stage				
	application from the Internation				· Olago				
* 5	See the attached detailed Office action	•	,	t received.					
			·						
Attachmen	t(s)	•							
1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) A) Interview Summary (PTO-413) Paper No(s)/Mail Date									
	e of Draftsperson's Patent Drawing Review (P mation Disclosure Statement(s) (PTO-1449 or I			(s)/Mail Date Informal Patent Application (PT	·O-152)				
	r No(s)/Mail Date		6) 🔲 Other:	• • • • • • • • • • • • • • • • • • • •					

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 1-10, drawn to methods of treating a patient with an ophthalmic disease

caused by a mutation in the gene GLC1A utilizing an aminoglycoside antibiotic

Page 2

compound, classified in class 514, subclass 912.

II. Claims 1-10, drawn to methods of treating a patient with an ophthalmic disease

caused by a mutation in the gene CYP1B1 utilizing an aminoglycoside antibiotic

compound, classified in class 514, subclass 912.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are each separate and distinct from each other as they are drawn to

differing methods having different steps, different goals and leading to differing results.

Because these inventions are distinct for the reasons given above and the search required

for the various groups would not be coextensive in scope, restriction for examination purposes as

indicated is proper.

Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art because of their recognized divergent subject matter, restriction for

examination purposes as indicated is proper.

Application/Control Number: 10/085,322

Art Unit: 1645

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Page 3

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert A. Zeman whose telephone number is (571) 272-0866. The examiner can normally be reached on Monday - Thursday 7 am - 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov.

Art Unit: 1645

Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ROBERT A. ZEMAN PATENT EXAMINER

December 27, 2005